Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.
暂无分享,去创建一个
G. Otto | B. Sido | A. Bierhaus | Y. Zhang | Y. Deng | J. Greten | U. Ritthaler | M. Abel | J. Allenberg | H. Roth | Youming Zhang | Angelika Bierhaus | A. Bierhaus
[1] C. W. Scott,et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[2] R. Bucala,et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[3] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[4] J. van Lunzen,et al. Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor. , 1994, The American journal of pathology.
[5] R. Bucala,et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. , 1993, The American journal of pathology.
[6] S. Gordon,et al. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor , 1993, Nature.
[7] N. Morisaki,et al. Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. , 1993, Biochemical and biophysical research communications.
[8] A. Schmidt,et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.
[9] M. Portero,et al. Mechanisms of glycation in atherogenesis. , 1993, Medical hypotheses.
[10] S. Krungkrai,et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[11] Martina,et al. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.
[12] M. Suthanthiran,et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.
[13] J. Baynes,et al. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.
[14] S. Ogawa,et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[15] L. Moldawer,et al. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. , 1989, The Journal of clinical investigation.
[16] H. Gerlach,et al. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.
[17] K. Manogue,et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.
[18] A. Cerami,et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.
[19] C. Elmets,et al. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. , 1986, The New England journal of medicine.